OncoMatch/Clinical Trials/NCT06598007
A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors
Is NCT06598007 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1/2 trial studies multiple treatments including CT3001 and FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin) for solid tumor, adult.
Treatment: CT3001 · FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin) — This is an FIH, multicenter, open-label, dose escalation and dose expansion/dose optimization study of CT3001, which will be conducted in 2 phases: Phase 1 and Phase 2b. Phase 1 will be a standard 3+3 dose escalation and dose finding study in patients with advanced solid tumors for whom there is no available therapy (or patients are not candidates for such therapy) for the assessment of DLTs at up to 7 dose levels of CT3001. Phase 2b is a dose finding/dose optimization study of CT3001 in combination with SOC chemotherapy (FOLFOX) to evaluate the safety and preliminary efficacy of CT3001 in patients with advanced CRC who are eligible for re-engaging FOLFOX-based chemotherapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Tumor Agnostic
Colorectal Cancer
Pancreatic Cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: concurrent anticancer treatment
Exception: phase 2b: standard care chemotherapy (folfox-based regimen) for advanced crc patients is allowed
Lab requirements
Blood counts
absolute neutrophil count ≥ 1.5 × 10^9/l without growth factor support in the 2 weeks prior to study entry; hemoglobin ≥9.0 g/dl without transfusion, growth factor support, or other supportive medication in the 2 weeks prior to study entry; platelet count ≥ 75 × 10^9/l without transfusion in 2 weeks prior to study entry
Kidney function
serum creatinine clearance (crcl) > 60 ml/min, as per the cockcroft-gault equation
Liver function
serum tbil < 1.5 × uln; ast and alt < 3 × uln
Cardiac function
qtcf interval > 470 ms (determined by average of 3 readings on triplicate 12-lead ecg) or history of additional risk factors for torsade de pointes (e.g., heart failure, hypokalemia, family history of long-qt syndrome) or current use of medications that prolong the qtcf interval
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06598007 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior concurrent anticancer treatment disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages